NASDAQ$BCYC
Bicycle Therapeutics plc · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
Bicycle Therapeutics reported financial results for Q4 2024 and provided corporate updates.
Bicycle Therapeutics reported promising anti-tumor activity and a differentiated safety profile for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer. The company's cash and cash equivalents were $879.5 million as of December 31, 2024, expected to provide financial runway into 2H 2027.
- Zelenectide pevedotin plus pembrolizumab show promising anti-tumor activity in first-line metastatic urothelial cancer.
- Duravelo-2 dose selection data is expected in 2H 2025.
- FDA granted Fast Track designation to zelenectide pevedotin for triple-negative breast cancer and NSCLC.
- Cash and cash equivalents of $879.5 million as of December 31, 2024, expected to provide financial runway into 2H 2027.
Headline financials
Revenue & EPS history
Bicycle · Revenue · Quarterly
$3.71M
Forward guidance
Bicycle Therapeutics is focused on advancing its pipeline and executing its research and development programs.
Tailwinds
- Continue topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab continue to show promising anti-tumor activity
- Advancing radiopharmaceuticals pipeline, with additional MT1-MMP human imaging data expected in mid-2025
- First EphA2 human imaging data planned for 2H 2025
- Several Phase 1/2 trials expected to start in 2025
- Financial runway into the second half of 2027
Headwinds
- Uncertainties inherent in research and development
- Risk that Bicycle Therapeutics may not realize the intended benefits of its technology, partnerships or NECTIN4 gene-amplification strategy
- Timing of results from clinical trials
- Risk that trials may have unsatisfactory outcomes
- Potential adverse effects arising from the testing or use of Bicycle Therapeutics’ product candidates
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+1.2%
Avg return
Earnings day
-1.6%
Avg return
5 days after
+0.1%
Avg return
30 days after
52%
14 / 27 earnings
Positive
+19.3%
Q4 2019
Best reaction
-10.8%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.2% | +3.6% | -0.8% | |
| Q4 2025 | -4.2% | -13.9% | +1.8% | |
| Q3 2025 | +6.7% | -16.0% | -8.6% | |
| Q1 2025 | +6.1% | -13.6% | -4.0% | |
| Q4 2024 | -1.3% | -2.5% | -18.3% | |
| Q3 2024 | -5.5% | -2.2% | -15.1% | |
| Q2 2024 | -0.7% | +2.1% | -10.0% | |
| Q1 2024 | +1.6% | -4.6% | -8.3% | |
| Q4 2023 | +3.1% | +9.5% | +14.9% | |
| Q3 2023 | +1.2% | -0.7% | -2.3% | |
| Q2 2023 | +1.3% | -2.8% | -4.1% | |
| Q1 2023 | -0.4% | +2.5% | +15.7% | |
| Q4 2022 | -1.9% | -5.5% | -6.2% | |
| Q3 2022 | -3.2% | +0.8% | +29.6% | |
| Q2 2022 | +14.8% | +17.7% | +12.8% | |
| Q1 2022 | -10.8% | -22.6% | -33.6% | |
| Q4 2021 | -1.2% | -9.7% | -7.6% | |
| Q3 2021 | +0.7% | +2.5% | -6.8% | |
| Q2 2021 | +1.8% | +2.3% | +36.0% | |
| Q1 2021 | +1.9% | -1.3% | -5.5% | |
| Q4 2020 | +1.9% | +2.0% | +3.8% | |
| Q3 2020 | -1.5% | +3.1% | +5.2% | |
| Q2 2020 | -0.2% | +0.0% | +5.8% | |
| Q1 2020 | +0.7% | +6.6% | +23.2% | |
| Q4 2019 | +19.3% | +1.5% | -2.3% | |
| Q3 2019 | -4.2% | -7.7% | -4.8% | |
| Q2 2019 | +5.9% | +5.4% | -6.6% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro